Ikarian Capital, LLC Bei Gene, Ltd. Call Options Transaction History

Ikarian Capital, LLC

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$143.93 - $224.51 $4.29 Million - $6.69 Million	29,800 New	29,800 $6.69 Million
Q2 2021 Aug 16, 2021	SELL	$292.75 - $367.01 $3.07 Million - $3.85 Million	-10,500 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$260.64 - $382.12 $2.74 Million - $4.01 Million	10,500 New	10,500 $3.66 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.2B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.